- BridgeBio adds $1B as it prepares three more drug launchesBridgeBio Pharma has reloaded with about $1 billion in a preferred equity deal to bolster its reserves ahead of three potential drug launches over the next year. The California biotech, which for…Endpoints · 27d ago↗ source
- Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal<figure><div><img src="https://imgproxy.divecdn.com/rFr9RThJC2782402VMoj7B8WOeODiV2bfIpEN0A2SvU/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS84LmpwZw==.webp"/></div></figure><p…BioPharma Dive · 27d ago↗ source
- 92Bio revives a T cell engager it had transferred to AmgenA small California startup is reviving an experimental T cell engager that its scientists originally developed but had handed off to Amgen years ago. After repeatedly saying it would bring the drug…